Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-16

PTC THERAPEUTICS, INC. (PTCT)

CEO Matthew Klein was paid $23,266,326 in fiscal year 2025, ↑ up 214.0% from fiscal year 2024, the 94th percentile of its disclosed peer group (SEC filing 0001104659-26-045528 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$23,266,326 ↑
Matthew Klein total, FY2025
94th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
97.95%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

PTCT's next annual pay disclosure, estimated April 20, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Matthew Klein$958,500$0$16,593,800$4,399,760$1,294,000$0$20,266$23,266,326
Chief Executive Officer
Eric Pauwels613,15001,023,8801,382,782517,800025,3563,562,968
Chief Business Officer
Pierre Gravier579,16701,047,1501,414,209488,600021,6603,550,786
Chief Financial Officer
Lee Golden574,6670930,8001,257,074482,800023,8383,269,179
Executive Vice President and Chief Medical Officer
Neil Almstead582,5000884,2601,194,221467,400030,6743,159,055
Chief Technical Operations Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Matthew Klein$23,266,326$7,410,765$8,937,025↑ +15,855,561
Eric Pauwels3,562,9682,398,4702,412,590↑ +1,164,498
Pierre Gravier3,550,7862,227,6542,734,475↑ +1,323,132
Lee Golden3,269,1792,248,0392,394,995↑ +1,021,140
Neil Almstead3,159,0552,318,8082,174,776↑ +840,247

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read PTC THERAPEUTICS, INC.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper PTCT reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the PTC THERAPEUTICS, INC. Peer Teardown Report

$23,266,326 Matthew Klein total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 16, 2026 · Source: 0001104659-26-045528 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for PTCT

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
PTCTon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order PTCT

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against PTCT
31 companies name PTCT as a compensation peer

The list of companies that name PTCT as a peer is temporarily unavailable — recheck shortly.

Get the PTC THERAPEUTICS, INC. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Alethia YoungIndependent Director$475,905
Allan JacobsonIndependent Director$547,405
David P. SouthwellIndependent Director$494,405
Emma ReeveIndependent Director$507,405
Glenn D. Steele JrIndependent Director$477,405
Jerome B. ZeldisIndependent Director$463,905
Jessica ChutterIndependent Director—
Mary SmithIndependent Director$479,405
Michael SchmertzlerChair of the Board$896,310
Stephanie S. OkeyIndependent Director$471,905
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Matthew B. KleinDirector2026-04-21D2,850$71$202,094CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D1,90079150,689CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08A2,74047127,520CommonForm 4 ↗
Dividend-equivalent accruals2026-05-08—800——1 insider, 1 accrual row
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D2,74000Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D6007947,568CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D2007815,600CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08A8004737,232CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D8407865,713CommonForm 4 ↗
Matthew B. KleinDirector2026-05-13A12,50000CommonForm 4 ↗
Matthew B. KleinDirector2026-05-14D6797349,608CommonForm 4 ↗
Matthew B. KleinDirector2026-05-14D2,10073153,468CommonForm 4 ↗
Matthew B. KleinDirector2026-05-14D2,57272186,367CommonForm 4 ↗
Matthew B. KleinDirector2026-05-14D7,22173527,711CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-15A2,8122672,240CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-15D2,35672169,820CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-15D2,81200Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-15D4567333,138CommonForm 4 ↗
Eric PauwelsCHIEF BUSINESS OFFICER2026-06-10D17,56600Derivative, Class A CommonForm 4 ↗
Eric PauwelsCHIEF BUSINESS OFFICER2026-06-10D3,71175278,325CommonForm 4 ↗
Eric PauwelsCHIEF BUSINESS OFFICER2026-06-10D17,566751,317,450CommonForm 4 ↗
Eric PauwelsCHIEF BUSINESS OFFICER2026-06-10A17,56618316,364CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D1,70379133,686CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D1,85079146,594CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D3097924,488CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D6,60079518,100CommonForm 4 ↗
Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER2026-06-17D19,686761,487,474CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17A2,0124793,638CommonForm 4 ↗
Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER2026-06-17A19,68626505,733CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D2,01200Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D8,51000Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17A8,51047396,055CommonForm 4 ↗
Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER2026-06-17D19,68600Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-22D11,61981943,579CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-22A23,74926610,112CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-22D23,74900Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-22D12,13081977,799CommonForm 4 ↗
Dividend-equivalent accruals2026-06-24—401——1 insider, 1 accrual row
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24D4,92285418,518CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24D4018534,089CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24A4,92238187,528CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24A4013815,278CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24D4,92200Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-06-25—1,101——1 insider, 2 accrual rows
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D19,85900Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25A19,85938756,628CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D5828549,610CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D8,52285726,586CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D4198636,197CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25A1,0013838,138CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D100878,700CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25A100393,942CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D11,33787980,764CommonForm 4 ↗
Dividend-equivalent accruals2026-06-26—412——1 insider, 1 accrual row
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26D7,71800Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26D7,71885658,037CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26A7,71838294,056CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26D4128535,115CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26A4123815,697CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D4268536,329CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D2,81300Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D2,22600Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D7458664,353CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D2,47487215,312CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D8,78685749,885CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D18,87600Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-07-06—811——1 insider, 1 accrual row
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D10,09086870,969CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06A18,87638719,176CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D6018651,914CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D5198644,551CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D3858633,241CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D3138326,010CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D2,47400Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06A2,4743997,525CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06A8113830,899CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D6458655,367CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D1,0368487,449CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D3878332,160CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06A2,81347130,917CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D8338470,314CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06A2,2663989,326CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07D24,61300Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07D9,28889830,719CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07D11,369891,012,182CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07A24,61339970,244CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07D3,95687344,845CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-09A2,46447114,675CommonForm 4 ↗
Mary SmithDirector2026-07-09D5,83400Derivative, Class A CommonForm 4 ↗
Mary SmithDirector2026-07-09D10,00000Derivative, Class A CommonForm 4 ↗
Mary SmithDirector2026-07-09A5,83443250,570CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-09D2,46400Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-09D2,46490222,376CommonForm 4 ↗
Mary SmithDirector2026-07-09D5,83490525,060CommonForm 4 ↗
Mary SmithDirector2026-07-09D10,00090900,000CommonForm 4 ↗
Mary SmithDirector2026-07-09A10,00043429,500CommonForm 4 ↗
Pierre GravierCHIEF FINANCIAL OFFICER2026-07-14D3,49480280,743CommonForm 4 ↗
Dividend-equivalent accruals2026-07-28—1,738——1 insider, 1 accrual row
Hege Elisabeth Sollie-ZetlmayerDirector2026-07-28A3,47500Derivative, Class A CommonForm 4 ↗
Hege Elisabeth Sollie-ZetlmayerDirector2026-07-28A2,00000CommonForm 4 ↗
Hege Elisabeth Sollie-ZetlmayerDirector2026-07-28A4,00000CommonForm 4 ↗
Matthew B. KleinDirector2026-08-04D10,29269705,722CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-08-17D1,84472133,487CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-08-17D2,81300Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-08-17D9697370,640CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-08-17A2,8132672,266CommonForm 4 ↗
Michael SchmertzlerDirector2026-08-19D7,16574527,846Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-19D5,33573388,708Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-20D6917350,388Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-20D2,39072171,793Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-20D9,41971666,677Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-26D6,87473500,015Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-26D5,62673411,711Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-27D11,89072850,730Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-27D6107244,054Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-09D5726939,279Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-09D9,42868639,124Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-10D10,00067673,400Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-16D7,00667471,854Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-16D2,99467199,341Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-17D3766825,737CommonForm 4 ↗
Michael SchmertzlerDirector2026-09-17D9,62468652,796Common, indirectForm 4 ↗
Glenn D. Steele JrDirector2026-09-30D12,00000Derivative, Class A CommonForm 4 ↗
Glenn D. Steele JrDirector2026-09-30D12,00065781,920CommonForm 4 ↗
Glenn D. Steele JrDirector2026-09-30A12,00011134,760CommonForm 4 ↗
Dividend-equivalent accruals2026-10-05—1,638——1 insider, 1 accrual row
Mark Elliott BouldingEXEC. VP AND CLO2026-10-05D1,63864104,881CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-05A1,6383964,570CommonForm 4 ↗
Dividend-equivalent accruals2026-10-06—435——1 insider, 1 accrual row
Mark Elliott BouldingEXEC. VP AND CLO2026-10-06D4356427,910CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-06A4353917,148CommonForm 4 ↗
Michael SchmertzlerDirector2026-10-07D53643,389Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-10-07D2,44763155,091Common, indirectForm 4 ↗
Dividend-equivalent accruals2026-10-09—192——1 insider, 1 accrual row
Mark Elliott BouldingEXEC. VP AND CLO2026-10-09D1926412,338CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-09A192397,569CommonForm 4 ↗
Michael SchmertzlerDirector2026-10-14D3826022,973Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-10-14D2,11860126,063Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 139 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Matthew B. KleinDirector2026-04-21D2,850$71$202,094CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D1,90079150,689CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08A2,74047127,520CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D80000Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D2,74000Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D6007947,568CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D2007815,600CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08A8004737,232CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-08D8407865,713CommonForm 4 ↗
Matthew B. KleinDirector2026-05-13A12,50000CommonForm 4 ↗
Matthew B. KleinDirector2026-05-14D6797349,608CommonForm 4 ↗
Matthew B. KleinDirector2026-05-14D2,10073153,468CommonForm 4 ↗
Matthew B. KleinDirector2026-05-14D2,57272186,367CommonForm 4 ↗
Matthew B. KleinDirector2026-05-14D7,22173527,711CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-15A2,8122672,240CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-15D2,35672169,820CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-15D2,81200Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-05-15D4567333,138CommonForm 4 ↗
Eric PauwelsCHIEF BUSINESS OFFICER2026-06-10D17,56600Derivative, Class A CommonForm 4 ↗
Eric PauwelsCHIEF BUSINESS OFFICER2026-06-10D3,71175278,325CommonForm 4 ↗
Eric PauwelsCHIEF BUSINESS OFFICER2026-06-10D17,566751,317,450CommonForm 4 ↗
Eric PauwelsCHIEF BUSINESS OFFICER2026-06-10A17,56618316,364CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D1,70379133,686CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D1,85079146,594CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D3097924,488CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D6,60079518,100CommonForm 4 ↗
Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER2026-06-17D19,686761,487,474CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17A2,0124793,638CommonForm 4 ↗
Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER2026-06-17A19,68626505,733CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D2,01200Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17D8,51000Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-06-17A8,51047396,055CommonForm 4 ↗
Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER2026-06-17D19,68600Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-22D11,61981943,579CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-22A23,74926610,112CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-22D23,74900Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-22D12,13081977,799CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24D40100Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24D4,92285418,518CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24D4018534,089CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24A4,92238187,528CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24A4013815,278CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-24D4,92200Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D10000Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D19,85900Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D1,00100Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25A19,85938756,628CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D5828549,610CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D8,52285726,586CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D4198636,197CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25A1,0013838,138CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D100878,700CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25A100393,942CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-25D11,33787980,764CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26D41200Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26D7,71800Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26D7,71885658,037CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26A7,71838294,056CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26D4128535,115CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-06-26A4123815,697CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D4268536,329CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D2,81300Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D2,22600Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D7458664,353CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D2,47487215,312CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D8,78685749,885CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D18,87600Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D81100Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D10,09086870,969CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06A18,87638719,176CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D6018651,914CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D5198644,551CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D3858633,241CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D3138326,010CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06D2,47400Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06A2,4743997,525CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-06A8113830,899CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D6458655,367CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D1,0368487,449CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D3878332,160CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06A2,81347130,917CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06D8338470,314CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-07-06A2,2663989,326CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07D24,61300Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07D9,28889830,719CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07D11,369891,012,182CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07A24,61339970,244CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-07D3,95687344,845CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-09A2,46447114,675CommonForm 4 ↗
Mary SmithDirector2026-07-09D5,83400Derivative, Class A CommonForm 4 ↗
Mary SmithDirector2026-07-09D10,00000Derivative, Class A CommonForm 4 ↗
Mary SmithDirector2026-07-09A5,83443250,570CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-09D2,46400Derivative, Class A CommonForm 4 ↗
Neil AlmsteadCHIEF TECHNICAL OPS OFFICER2026-07-09D2,46490222,376CommonForm 4 ↗
Mary SmithDirector2026-07-09D5,83490525,060CommonForm 4 ↗
Mary SmithDirector2026-07-09D10,00090900,000CommonForm 4 ↗
Mary SmithDirector2026-07-09A10,00043429,500CommonForm 4 ↗
Pierre GravierCHIEF FINANCIAL OFFICER2026-07-14D3,49480280,743CommonForm 4 ↗
Hege Elisabeth Sollie-ZetlmayerDirector2026-07-28A1,73800Derivative, Class A CommonForm 4 ↗
Hege Elisabeth Sollie-ZetlmayerDirector2026-07-28A3,47500Derivative, Class A CommonForm 4 ↗
Hege Elisabeth Sollie-ZetlmayerDirector2026-07-28A2,00000CommonForm 4 ↗
Hege Elisabeth Sollie-ZetlmayerDirector2026-07-28A4,00000CommonForm 4 ↗
Matthew B. KleinDirector2026-08-04D10,29269705,722CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-08-17D1,84472133,487CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-08-17D2,81300Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-08-17D9697370,640CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-08-17A2,8132672,266CommonForm 4 ↗
Michael SchmertzlerDirector2026-08-19D7,16574527,846Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-19D5,33573388,708Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-20D6917350,388Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-20D2,39072171,793Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-20D9,41971666,677Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-26D6,87473500,015Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-26D5,62673411,711Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-27D11,89072850,730Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-08-27D6107244,054Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-09D5726939,279Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-09D9,42868639,124Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-10D10,00067673,400Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-16D7,00667471,854Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-16D2,99467199,341Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-09-17D3766825,737CommonForm 4 ↗
Michael SchmertzlerDirector2026-09-17D9,62468652,796Common, indirectForm 4 ↗
Glenn D. Steele JrDirector2026-09-30D12,00000Derivative, Class A CommonForm 4 ↗
Glenn D. Steele JrDirector2026-09-30D12,00065781,920CommonForm 4 ↗
Glenn D. Steele JrDirector2026-09-30A12,00011134,760CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-05D1,63800Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-05D1,63864104,881CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-05A1,6383964,570CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-06D43500Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-06D4356427,910CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-06A4353917,148CommonForm 4 ↗
Michael SchmertzlerDirector2026-10-07D53643,389Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-10-07D2,44763155,091Common, indirectForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-09D19200Derivative, Class A CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-09D1926412,338CommonForm 4 ↗
Mark Elliott BouldingEXEC. VP AND CLO2026-10-09A192397,569CommonForm 4 ↗
Michael SchmertzlerDirector2026-10-14D3826022,973Common, indirectForm 4 ↗
Michael SchmertzlerDirector2026-10-14D2,11860126,063Common, indirectForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Eric PauwelsRSU2025-01-03——22,000—$1,023,880
Neil AlmsteadRSU2025-01-03——19,000—884,260
Matthew KleinOPTION2025-01-03——175,000—4,399,760
Neil AlmsteadOPTION2025-01-03——47,500—1,194,221
Pierre GravierRSU2025-01-03——22,500—1,047,150
Lee GoldenRSU2025-01-03——20,000—930,800
Matthew KleinPSU2025-12-02—100,000—200,00013,336,000
Eric PauwelsOPTION2025-01-03——55,000—1,382,782
Lee GoldenOPTION2025-01-03——50,000—1,257,074
Matthew KleinRSU2025-01-03——70,000—3,257,800
Pierre GravierOPTION2025-01-03——56,250—1,414,209
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Eric Pauwels$1,023,880$0$1,382,7820.0%
Neil Almstead884,26001,194,2210.0%
Matthew Klein3,257,80013,336,0004,399,76063.5%
Pierre Gravier1,047,15001,414,2090.0%
Lee Golden930,80001,257,0740.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Eric PauwelsRSU1,150—$87,354
Lee GoldenOption85038.1—
Eric PauwelsRSU9,000—683,640
Lee GoldenRSU5,320—404,107
Neil AlmsteadRSU3,000—227,880
Lee GoldenRSU20,000—1,519,200
Pierre GravierRSU14,250—1,082,430
Neil AlmsteadRSU8,500—645,660
Matthew KleinRSU13,000—987,480
Neil AlmsteadRSU19,000—1,443,240
Lee GoldenRSU2,039—154,882
Matthew KleinRSU5,250—398,790
Lee GoldenRSU1,500—113,940
Eric PauwelsOption3,93838.1—
Eric PauwelsOption55,00046.54—
Lee GoldenOption7,87552.85—
Neil AlmsteadOption3,37538.1—
Neil AlmsteadRSU14,250—1,082,430
Pierre GravierRSU22,500—1,709,100
Matthew KleinRSU18,750—1,424,250
Matthew KleinOption24,37552.96—
Lee GoldenOption3,56339.42—
Matthew KleinRSU70,000—5,317,200
Matthew KleinRSU50,000—3,798,000
Pierre GravierRSU13,000—987,480
Lee GoldenRSU4,200—319,032
Matthew KleinRSU52,500—3,987,900
Eric PauwelsRSU16,500—1,253,340
Matthew KleinPSU100,000—7,596,000
Pierre GravierRSU1,550—117,738
Lee GoldenOption62538.1—
Matthew KleinOption98,43825.69—
Pierre GravierOption56,25046.54—
Eric PauwelsRSU22,000—1,671,120
Lee GoldenRSU15,000—1,139,400
Lee GoldenOption28,12525.69—
Matthew KleinPSU25,000—1,899,000
Matthew KleinPSU15,625—1,186,875
Matthew KleinOption3,28238.1—
Matthew KleinRSU7,813—593,475
Neil AlmsteadRSU3,600—273,456
Pierre GravierOption26,71925.69—
Eric PauwelsOption30,93825.69—
Neil AlmsteadOption47,50046.54—
Eric PauwelsRSU4,200—319,032
Lee GoldenRSU1,300—98,748
Matthew KleinOption175,00046.54—
Neil AlmsteadOption11,32939.42—
Matthew KleinOption20,31339.42—
Pierre GravierOption28,43839.82—
Eric PauwelsOption14,06339.42—
Lee GoldenOption50,00046.54—
Neil AlmsteadOption26,71925.69—
05

Incentive-plan design — the Compensation Discussion & Analysis

PTC's compensation program is designed to be competitive with peers and to motivate executives to achieve short-term and long-term strategy by placing a significant portion of compensation 'at risk'. The program aims to attract and retain qualified management while aligning the interests of executive officers with long-term stockholders through equity awards with time-based vesting schedules.

CEO STI target (% of salary)80%
CEO LTI target (% of salary)—
Independent consultantFrederic W. Cook & Co., Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0271,166,2041,492,80124,29097.95%Passed
20252025-06-1760,479,1571,979,31044,71196.83%Passed
20242024-06-1864,786,2561,278,678148,97998.06%Passed
20232023-06-0665,318,1231,464,75621,68897.81%Passed
20222022-06-0863,004,1061,917,41868,85797.05%Passed
20212021-06-0962,819,7891,238,77748,15698.07%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0297.95%a
20252025-06-1796.83%b
20242024-06-1898.06%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Michael SchmertzlerIndependent · Board Chair · Nominating and Corporate Governance · Development · Compensation$81,500$372,320$442,490—$0$896,310
Allan JacobsonIndependent · Development (Chair)50,000186,160221,245—90,000547,405
Allan Jacobson, Ph.DIndependent · Development (Chair)50,000186,160221,245—90,000547,405
Emma ReeveIndependent · Audit (Chair) · Compensation100,000186,160221,245—0507,405
David P. SouthwellIndependent · Audit · Compensation87,000186,160221,245—0494,405
Mary SmithIndependent · Audit · Compensation72,000186,160221,245—0479,405
Glenn D. Steele Jr., M.D., Ph.DIndependent · Compensation (Chair) · Development70,000186,160221,245—0477,405
Glenn D. Steele JrIndependent · Development · Compensation (Chair)70,000186,160221,245—0477,405
Alethia YoungIndependent · Audit · Nominating and Corporate Governance68,500186,160221,245—0475,905
Stephanie S. OkeyIndependent · Nominating and Corporate Governance (Chair)64,500186,160221,245—0471,905
Stephanie S. Okey, M.SIndependent · Nominating and Corporate Governance (Chair)64,500186,160221,245—0471,905
Jerome B. ZeldisIndependent · Nominating and Corporate Governance · Development56,500186,160221,245—0463,905
Jerome B. Zeldis, M.D., Ph.DIndependent · Nominating and Corporate Governance · Development56,500186,160221,245—0463,905
Jessica ChutterIndependent · Newly elected000—00
Matthew B. KleinEmployee director · Development—————0
Matthew B. Klein, M.D., M.S., F.A.C.SEmployee director · Development—————0
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 14,500
Stock ownership guideline$150,000
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$891,000
Equity awards (grant-date value)$2,606,240
All other compensation$180,000
Total cost of the board$3,677,240

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies PTC THERAPEUTICS, INC. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including PTC THERAPEUTICS, INC..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis, Inc.2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2PTC THERAPEUTICS, INC.2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
3Halozyme Therapeutics, Inc.2025Helen Torley1,000,00019,350,1451,650,0141,147,50023,166,223
4Madrigal Pharmaceuticals Corporation2025Bill Sibold918,53112,297,8504,537,1461,438,81419,206,341
5Jazz Pharmaceuticals plc2025Renee Gala1,003,26916,138,43301,980,00019,151,558
6Supernus Pharmaceuticals, Inc.2025Jack Khattar1,036,0006,535,0297,031,545846,93015,501,557
7Corcept Therapeutics Incorporated2025Joseph Belanoff1,182,333012,907,718015,303,551
8Insmed, Inc.2025William Lewis854,5502,999,9409,000,0331,495,46314,467,393
9Blueprint Medicines Corp.2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
10Ionis Pharmaceuticals, Inc.2025Brett Monia1,051,7768,444,8381,438,105013,350,777
11Pacira BioSciences, Inc.2025Frank Lee935,3089,215,5000738,81011,636,917
12Ultragenyx Pharmaceutical Inc.2025Emil Kakkis861,1008,364,9381,847,356299,66311,405,535
13Apellis Pharmaceuticals, Inc.2024Cedric Francois793,1934,779,8324,787,768010,957,451
14Axsome Therapeutics, Inc.2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
15Intra-Cellular Therapies, Inc.2023Sharon Mates891,6537,749,9840010,086,413
16Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
17ACADIA Pharmaceuticals Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
18Alkermes plc2025Richard Pops1,250,76905,020,8121,626,0007,915,081
19Harmony Biosciences Holdings, Inc.2025Jeffrey Dayno743,6001,976,5204,599,000558,0007,899,535
20Sarepta Therapeutics, Inc.2025Douglas Ingram1,171,4256,000,0050649,0007,840,666

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
PTC THERAPEUTICS, INC.not disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
ACADIA Pharmaceuticals Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Alkermes plc130%PRSU 53 · RSU 24 · Option 23Yes — Relative Total Shareholder Return (TSR)Alpine Rewards LLC
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Apellis Pharmaceuticals, Inc.90.74%RSU 50 · PSU 50not disclosedPay Governance
Axsome Therapeutics, Inc.150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
Blueprint Medicines Corp.130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon
Corcept Therapeutics IncorporatedDr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%%Stock Options 100not disclosednot disclosed
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Halozyme Therapeutics, Inc.127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
Harmony Biosciences Holdings, Inc.100%not disclosednot disclosedPay Governance
Insmed, Inc.175%Options 75 · RSU 25NoWillis Towers Watson (WTW)
Intra-Cellular Therapies, Inc.not disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Ionis Pharmaceuticals, Inc.not disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Jazz Pharmaceuticals plc150%PSU 50 · RSU 50Yes — Relative TSRAon
Madrigal Pharmaceuticals Corporation195%PSU 33 · RSU 33 · Options 33Yes — Relative TSR vs Nasdaq Biotechnology IndexCompensia
Pacira BioSciences, Inc.90%RSU 80 · PSU 20NoAon
Sarepta Therapeutics, Inc.100%PSU 50 · Option 25 · RSU 25NoFW Cook
Supernus Pharmaceuticals, Inc.not disclosednot disclosedNoAon
Ultragenyx Pharmaceutical Inc.44%PSU 60 · RSU 20 · Options 20Yes — Relative TSRAon's Human Capital Solutions Practice

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at PTC THERAPEUTICS, INC. in fiscal 2025?
As disclosed, Matthew Klein (Chief Executive Officer) was the highest-paid executive at PTC THERAPEUTICS, INC. in fiscal 2025, with total compensation of $23,266,326.
How does PTC THERAPEUTICS, INC.'s chief executive pay compare to its disclosed peer group?
As disclosed, Matthew Klein's total compensation ranked at the 94th percentile of PTC THERAPEUTICS, INC.'s disclosed peer group.
How did shareholders vote on PTC THERAPEUTICS, INC.'s executive compensation?
As disclosed, 97.95% of shareholders supported PTC THERAPEUTICS, INC.'s executive compensation in the latest say-on-pay vote.
How much does PTC THERAPEUTICS, INC. spend in total on board compensation for fiscal 2025?
As disclosed, PTC THERAPEUTICS, INC. reported total board compensation of $3,677,240 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Matthew KleinDEF 14A2026-04-200001104659-26-045528Section “Summary Compensation Table” · page 52. As printed: 23,266,326. Filing ↗
2Section 01, Eric PauwelsDEF 14A2026-04-200001104659-26-045528Section “Summary Compensation Table” · page 52. As printed: 3,562,968. Filing ↗
3Section 01, Pierre GravierDEF 14A2026-04-200001104659-26-045528Section “Summary Compensation Table” · page 52. As printed: 3,550,786. Filing ↗
4Section 01, Lee GoldenDEF 14A2026-04-200001104659-26-045528Section “Summary Compensation Table” · page 52. As printed: 3,269,179. Filing ↗
5Section 01, Neil AlmsteadDEF 14A2026-04-200001104659-26-045528Section “Summary Compensation Table” · page 52. As printed: 3,159,055. Filing ↗
6Section 03, Eric Pauwels RSUDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 970536–970545
7Section 03, Neil Almstead RSUDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 1013029–1013036
8Section 03, Matthew Klein OPTIONDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 914587–914596
9Section 03, Neil Almstead OPTIONDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 1005643–1005652
10Section 03, Pierre Gravier RSUDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 949476–949485
11Section 03, Lee Golden RSUDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 991551–991558
12Section 03, Matthew Klein PSUDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 928832–928842
13Section 03, Eric Pauwels OPTIONDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 963099–963108
14Section 03, Lee Golden OPTIONDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 984678–984687
15Section 03, Matthew Klein RSUDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 921452–921461
16Section 03, Pierre Gravier OPTIONDEF 14A1900-01-010001104659-26-045528Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 942552–942561
17Section 08, Michael SchmertzlerDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 896,310. Filing ↗machine: span 1908091–1908262
18Section 08, Allan JacobsonDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 547,405. Filing ↗machine: span 1916194–1916365
19Section 08, Allan Jacobson, Ph.DDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 547,405. Filing ↗machine: span 1916194–1916365
20Section 08, Emma ReeveDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 507,405. Filing ↗machine: span 1924070–1924241
21Section 08, David P. SouthwellDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 494,405. Filing ↗machine: span 1932224–1932395
22Section 08, Mary SmithDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 479,405. Filing ↗machine: span 1928133–1928304
23Section 08, Glenn D. Steele Jr., M.D., Ph.DDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 477,405. Filing ↗machine: span 1936026–1936197
24Section 08, Glenn D. Steele JrDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 477,405. Filing ↗machine: span 1936026–1936197
25Section 08, Alethia YoungDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 475,905. Filing ↗machine: span 1940381–1940552
26Section 08, Stephanie S. OkeyDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 471,905. Filing ↗machine: span 1919986–1920157
27Section 08, Stephanie S. Okey, M.SDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 471,905. Filing ↗machine: span 1919986–1920157
28Section 08, Jerome B. ZeldisDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 463,905. Filing ↗machine: span 1944176–1944347
29Section 08, Jerome B. Zeldis, M.D., Ph.DDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 463,905. Filing ↗machine: span 1944176–1944347
30Section 08, Jessica ChutterDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 0. Filing ↗
31Section 08, Matthew B. KleinDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 0. Filing ↗
32Section 08, Matthew B. Klein, M.D., M.S., F.A.C.SDEF 14A2026-04-200001104659-26-045528Section “Director Compensation”. As printed: 0. Filing ↗
33Section 02, Matthew B. Klein 2026-04-21Form 42026-04-230001808968-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Mark Elliott Boulding 2026-05-08Form 42026-05-120001578852-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Mark Elliott Boulding 2026-05-08Form 42026-05-120001578852-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Mark Elliott Boulding 2026-05-08Form 42026-05-120001578852-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Mark Elliott Boulding 2026-05-08Form 42026-05-120001578852-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Mark Elliott Boulding 2026-05-08Form 42026-05-120001578852-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Mark Elliott Boulding 2026-05-08Form 42026-05-120001578852-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Mark Elliott Boulding 2026-05-08Form 42026-05-120001578852-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Mark Elliott Boulding 2026-05-08Form 42026-05-120001578852-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Matthew B. Klein 2026-05-13Form 42026-05-150001808968-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Matthew B. Klein 2026-05-14Form 42026-05-150001808968-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Matthew B. Klein 2026-05-14Form 42026-05-150001808968-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Matthew B. Klein 2026-05-14Form 42026-05-150001808968-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Matthew B. Klein 2026-05-14Form 42026-05-150001808968-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Mark Elliott Boulding 2026-05-15Form 42026-05-190001578852-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Mark Elliott Boulding 2026-05-15Form 42026-05-190001578852-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Mark Elliott Boulding 2026-05-15Form 42026-05-190001578852-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Mark Elliott Boulding 2026-05-15Form 42026-05-190001578852-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Eric Pauwels 2026-06-10Form 42026-06-120001323212-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Eric Pauwels 2026-06-10Form 42026-06-120001323212-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Eric Pauwels 2026-06-10Form 42026-06-120001323212-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Eric Pauwels 2026-06-10Form 42026-06-120001323212-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Mark Elliott Boulding 2026-06-17Form 42026-06-220001578852-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Mark Elliott Boulding 2026-06-17Form 42026-06-220001578852-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Mark Elliott Boulding 2026-06-17Form 42026-06-220001578852-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Mark Elliott Boulding 2026-06-17Form 42026-06-220001578852-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Christine Marie Utter 2026-06-17Form 42026-06-220001707685-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Mark Elliott Boulding 2026-06-17Form 42026-06-220001578852-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Christine Marie Utter 2026-06-17Form 42026-06-220001707685-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Mark Elliott Boulding 2026-06-17Form 42026-06-220001578852-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Mark Elliott Boulding 2026-06-17Form 42026-06-220001578852-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Mark Elliott Boulding 2026-06-17Form 42026-06-220001578852-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Christine Marie Utter 2026-06-17Form 42026-06-220001707685-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Neil Almstead 2026-06-22Form 42026-06-240001578850-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Neil Almstead 2026-06-22Form 42026-06-240001578850-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Neil Almstead 2026-06-22Form 42026-06-240001578850-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Neil Almstead 2026-06-22Form 42026-06-240001578850-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Neil Almstead 2026-06-24Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Neil Almstead 2026-06-24Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Neil Almstead 2026-06-24Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Neil Almstead 2026-06-24Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Neil Almstead 2026-06-24Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Neil Almstead 2026-06-24Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Neil Almstead 2026-06-25Form 42026-06-260001578850-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Neil Almstead 2026-06-26Form 42026-06-300001578850-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Neil Almstead 2026-06-26Form 42026-06-300001578850-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Neil Almstead 2026-06-26Form 42026-06-300001578850-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Neil Almstead 2026-06-26Form 42026-06-300001578850-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Neil Almstead 2026-06-26Form 42026-06-300001578850-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Neil Almstead 2026-06-26Form 42026-06-300001578850-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Neil Almstead 2026-07-06Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Mark Elliott Boulding 2026-07-06Form 42026-07-080001578852-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Neil Almstead 2026-07-07Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Neil Almstead 2026-07-07Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Neil Almstead 2026-07-07Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Neil Almstead 2026-07-07Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Neil Almstead 2026-07-07Form 42026-07-080001578850-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Neil Almstead 2026-07-09Form 42026-07-130001578850-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Mary Smith 2026-07-09Form 42026-07-130001866044-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Mary Smith 2026-07-09Form 42026-07-130001866044-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Mary Smith 2026-07-09Form 42026-07-130001866044-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Neil Almstead 2026-07-09Form 42026-07-130001578850-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Neil Almstead 2026-07-09Form 42026-07-130001578850-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Mary Smith 2026-07-09Form 42026-07-130001866044-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Mary Smith 2026-07-09Form 42026-07-130001866044-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Mary Smith 2026-07-09Form 42026-07-130001866044-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Pierre Gravier 2026-07-14Form 42026-07-160001984065-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Hege Elisabeth Sollie-Zetlmayer 2026-07-28Form 42026-07-300002142653-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Hege Elisabeth Sollie-Zetlmayer 2026-07-28Form 42026-07-300002142653-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Hege Elisabeth Sollie-Zetlmayer 2026-07-28Form 42026-07-300002142653-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Hege Elisabeth Sollie-Zetlmayer 2026-07-28Form 42026-07-300002142653-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Matthew B. Klein 2026-08-04Form 42026-08-060001808968-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Mark Elliott Boulding 2026-08-17Form 42026-08-190001578852-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Mark Elliott Boulding 2026-08-17Form 42026-08-190001578852-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Mark Elliott Boulding 2026-08-17Form 42026-08-190001578852-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Mark Elliott Boulding 2026-08-17Form 42026-08-190001578852-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Michael Schmertzler 2026-08-19Form 42026-08-210001288952-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Michael Schmertzler 2026-08-19Form 42026-08-210001288952-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Michael Schmertzler 2026-08-20Form 42026-08-210001288952-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Michael Schmertzler 2026-08-20Form 42026-08-210001288952-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Michael Schmertzler 2026-08-20Form 42026-08-210001288952-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Michael Schmertzler 2026-08-26Form 42026-08-280001288952-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Michael Schmertzler 2026-08-26Form 42026-08-280001288952-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Michael Schmertzler 2026-08-27Form 42026-08-280001288952-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Michael Schmertzler 2026-08-27Form 42026-08-280001288952-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Michael Schmertzler 2026-09-09Form 42026-09-110001288952-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Michael Schmertzler 2026-09-09Form 42026-09-110001288952-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Michael Schmertzler 2026-09-10Form 42026-09-110001288952-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Michael Schmertzler 2026-09-16Form 42026-09-180001288952-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Michael Schmertzler 2026-09-16Form 42026-09-180001288952-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Michael Schmertzler 2026-09-17Form 42026-09-180001288952-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Michael Schmertzler 2026-09-17Form 42026-09-180001288952-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Glenn D. Steele Jr 2026-09-30Form 42026-10-020001269131-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Glenn D. Steele Jr 2026-09-30Form 42026-10-020001269131-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Glenn D. Steele Jr 2026-09-30Form 42026-10-020001269131-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Mark Elliott Boulding 2026-10-05Form 42026-10-070001578852-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Mark Elliott Boulding 2026-10-05Form 42026-10-070001578852-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Mark Elliott Boulding 2026-10-05Form 42026-10-070001578852-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Mark Elliott Boulding 2026-10-06Form 42026-10-070001578852-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Mark Elliott Boulding 2026-10-06Form 42026-10-070001578852-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Mark Elliott Boulding 2026-10-06Form 42026-10-070001578852-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Michael Schmertzler 2026-10-07Form 42026-10-090001288952-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Michael Schmertzler 2026-10-07Form 42026-10-090001288952-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Mark Elliott Boulding 2026-10-09Form 42026-10-130001578852-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Mark Elliott Boulding 2026-10-09Form 42026-10-130001578852-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Mark Elliott Boulding 2026-10-09Form 42026-10-130001578852-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Michael Schmertzler 2026-10-14Form 42026-10-160001288952-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Michael Schmertzler 2026-10-14Form 42026-10-160001288952-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
172Section 06, 2026 voteForm 8-K2026-06-050001104659-26-071040Item 5.07 · say-on-pay result. As reported: 97.95% (votes for as printed: 71,166,204). Filing ↗
173Section 06, 2025 voteForm 8-K2025-06-170001558370-25-008694Item 5.07 · say-on-pay result. As reported: 96.83% (votes for as printed: 60,479,157). Filing ↗
174Section 06, 2024 voteForm 8-K2024-06-200001558370-24-009313Item 5.07 · say-on-pay result. As reported: 98.06% (votes for as printed: 64,786,256). Filing ↗
175Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
176Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
177Section 09b board cost (computed)Computed——Cash 891,000 + equity 2,606,240 + all other 180,000 = 3,677,240, summed across the director compensation table rows.machine: formula: Σ = 3,677,240
178Exelixis, Inc., Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
179PTC THERAPEUTICS, INC. (subject), Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC THERAPEUTICS, INC.'s own proxy. As printed: 23,266,326. Filing ↗
180Halozyme Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
181Madrigal Pharmaceuticals Corporation, Section 10b CEO totalDEF 14A2026-04-280001308179-26-000352CEO total compensation as printed in Madrigal Pharmaceuticals Corporation's own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952
182Jazz Pharmaceuticals plc, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
183Supernus Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-300001104659-26-053111CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604
184Corcept Therapeutics Incorporated, Section 10b CEO totalDEF 14A2026-04-170001628280-26-025735CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514
185Insmed, Inc., Section 10b CEO totalDEF 14A2026-04-010001104506-26-000022CEO total compensation as printed in Insmed, Inc.'s own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563
186Blueprint Medicines Corp., Section 10b CEO totalDEF 14A2025-04-240001558370-25-005415CEO total compensation as printed in Blueprint Medicines Corp.'s own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162
187Ionis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗
188Pacira BioSciences, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050353CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168
189Ultragenyx Pharmaceutical Inc., Section 10b CEO totalDEF 14A2026-03-270001308179-26-000174CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007
190Apellis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
191Axsome Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
192Intra-Cellular Therapies, Inc., Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
193Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
194ACADIA Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗
195Alkermes plc, Section 10b CEO totalDEF 14A2026-04-060001193125-26-143977CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267
196Harmony Biosciences Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-030001104659-26-039449CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364
197Sarepta Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177247CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404
198Section 10a, Exelixis, Inc. reciprocityDEF 14A—0000939767-26-000046Exelixis, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
199Section 10a, Jazz Pharmaceuticals plc reciprocityDEF 14A—0001232524-26-000029Jazz Pharmaceuticals plc's most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗
200Section 10a, Supernus Pharmaceuticals, Inc. reciprocityDEF 14A—0001104659-26-053111Supernus Pharmaceuticals, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
201Section 10a, Insmed, Inc. reciprocityDEF 14A—0001104506-26-000022Insmed, Inc.'s most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗
202Section 10a, Axsome Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177610Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗
203Section 10a, Madrigal Pharmaceuticals Corporation reciprocityDEF 14A—0001308179-26-000352Madrigal Pharmaceuticals Corporation's most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗
204Section 10a, Sarepta Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177247Sarepta Therapeutics, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
205Section 10a, Halozyme Therapeutics, Inc. reciprocityDEF 14A—0001159036-26-000041Halozyme Therapeutics, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
206Section 10a, ACADIA Pharmaceuticals Inc. reciprocityDEF 14A—0001193125-26-174163ACADIA Pharmaceuticals Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
207Section 10a, Ionis Pharmaceuticals, Inc. reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
208Section 10a, Ultragenyx Pharmaceutical Inc. reciprocityDEF 14A—0001308179-26-000174Ultragenyx Pharmaceutical Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
209Section 10a, Blueprint Medicines Corp. reciprocityDEF 14A—0001558370-25-005415Blueprint Medicines Corp. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
210Section 10a, Harmony Biosciences Holdings, Inc. reciprocityDEF 14A—0001104659-26-039449Harmony Biosciences Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗
211Section 10a, Pacira BioSciences, Inc. reciprocityDEF 14A—0001104659-26-050353Pacira BioSciences, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
212Section 10a, Apellis Pharmaceuticals, Inc. reciprocityDEF 14A—0000950170-25-056966Apellis Pharmaceuticals, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
213Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗
214Section 10a, Intra-Cellular Therapies, Inc. reciprocityDEF 14A—0001628280-24-018986Intra-Cellular Therapies, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the PTC THERAPEUTICS, INC. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
PTCT Peer Teardown Report